SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors (NCT05642780)

🧪 Interventions in This Study

• SKB264 (DRUG)
• Pembrolizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (48 Sites)

Showing the first 25 of 48 sites.

• Community Clinical Research Center — Anderson, Indiana
• Norton Cancer Institute — Louisville, Kentucky
• Anne Arundel Medical Center (AAMC) — Annapolis, Maryland
• UT Health East Texas - Hope Cancer Center Tyler — Tyler, Minnesota
• Westchester Medical Center — Hawthorne, New York
• Texas Oncology, P.A. Amarillo, TX — Amarillo, Texas
• Texas Oncology, P.A. Austin, TX — Austin, Texas
• Oncology & Hematology Associates of Southwest Virginia, Inc. Roanoke, VA — Roanoke, Virginia
• Icon Cancer Centre Wesley — Auchenflower, Queensland
• Flinders Medical Centre — Bedford Park,
• Wollongong Hospital — Kogarah,
• Algemeen Ziekenhuis Klina — Brasschaat,
• Grand Hôpital de Charleroi - Site Notre-Dame — Charleroi,
• Cliniques Universitaires Saint-Luc — Woluwe-Saint-Lambert,
• BC Cancer - Kelowna — Kelowna, British Columbia
• Centre Hospitalier de l'Université de Montréal (CHUM) — Montreal,
• Sun Yat-Sen University Cancer Center — Guangzhou, Guangdong
• Affiliated Cancer Hospital of Guangxi Medical University — Nanning, Guangxi
• Hubei Cancer Hospital — Wuhan, Hubei
• Hunan Cancer Hospital — Changsha, Hunan
• Jilin Cancer Hospital — Changchun, Jinlin
• The Second Hospital of Dalian — Dalian, Liaoning
• Weifang People's Hospital — Weifang, Shandong
• The First Affiliated Hospital of Xi'an Jiaotong University — Xi’an, Shanxi
• Beijing Obstetrics and Gynecology Hospital, Capital Medical University — Beijing,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumor

• A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
• A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
• A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
• Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
• A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
• Concurrent Azeliragon With Craniospinal Irradiation — New York, New York

Explore by condition: All Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.